Skip to main content

Vertex’s latest FDA nod could boost sales by $150M: analyst

The Boston-based company said Tuesday that the FDA had approved its cystic fibrosis drug Kalydeco for use in more than 600 additional patients with the lung disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.